Breaking Down GuiZhou SanLi Pharmaceutical Co.,Ltd Financial Health: Key Insights for Investors

Guizhou Sanli Pharmaceutical Co., Ltd. (603439.SS) has been delivering striking top-line momentum - 2.14 billion yuan in 2024 revenue, up 31.16% year-on-year from 1.63 billion, with H1 2024 already at 920 million yuan (+45.91%) and Q2 contributing 498 million (+76.87%) - driven by strong demand for its Kaitoujian spray and a 46% revenue lift from the Hanfang integration; profitability shows mixed signals with a 2024 net profit of 274 million yuan (net margin ~12.8%) and Q3 net profit of 77 million (+35.17% YoY) even as Q1 2025 EPS slipped to 0.10 yuan from 0.14, while forward-looking metrics project revenue of 2.333B/2.93B/3.667B yuan and net profit of 354M/458M/583M for 2024-2026 and ROE rising toward 22.1% by 2026; balance-sheet and market measures point to improving stability with debt-to-asset projected to fall from 41.5% (2023) to 27.1% (2026), a market cap of 5.08 billion yuan (Oct 9, 2025), P/E at 21.64, P/S 2.87, a dividend yield of 2.82% (0.34 yuan/share), and active buybacks of 7,869,300 shares (1.92%) totaling 99.95 million yuan - read on for a detailed breakdown of liquidity, valuation, risks and what these numbers mean for investors.

GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Revenue Analysis

• 2024 full-year revenue: 2.14 billion yuan (up 31.16% vs. 2023: 1.63 billion yuan).
• 2023 revenue growth: +36.10% (vs. 2022).
• 2022 revenue growth: +27.94% (vs. 2021 baseline).
• H1 2024 revenue: 920 million yuan (H1 YoY +45.91%); Q2 2024 revenue: 498 million yuan (Q2 YoY +76.87%).
• Core product 'Kaitoujian' spray: expected Q2 2024 revenue growth >20% driven by strong market demand.
• Hanfang Pharmaceutical integration: contributed ~46% incremental revenue uplift to consolidated sales.

• Primary revenue drivers:
  • Kaitoujian spray: sustained market uptake and channel expansion (Q2 2024 growth >20%).
  • Hanfang Pharmaceutical integration: ~46% revenue accretion, broadened product portfolio and distribution.
  • Sales uplift in H1 2024: 920 million yuan with double-digit sequential acceleration in Q2.
• Revenue trajectory and guidance:
  • Company projects revenue of 2.333 billion yuan in 2024, rising to 2.93 billion in 2025 and 3.667 billion in 2026, implying continued mid-to-high-teens CAGR across the projection window.

GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Profitability Metrics

Key profitability figures for GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) reveal a company with solid margins and improving return on equity, alongside some short-term earnings variability.

• Reported net profit (2024, actual): 274 million yuan; implied net margin ~12.8%.
• Company net profit projections:
  • 2024: 354 million yuan (projected)
  • 2025: 458 million yuan (projected)
  • 2026: 583 million yuan (projected)
• Projected year-on-year growth rates: 2024 +20.9%, 2025 +29.4%, 2026 +27.2% (based on company projections).
• Return on equity (ROE): projected 20.0% in 2024, rising to 22.1% by 2026.
• Trailing performance indicators:
  • Net profit Q3 2024: 77 million yuan (+35.17% YoY).
  • Net profit margin for first three quarters of 2024: 13.74% (down 2.50 percentage points YoY).
  • EPS Q1 2025: 0.10 yuan vs 0.14 yuan in Q1 2024 (decline in quarterly earnings).

For additional context on the company's background and business model, see: GuiZhou SanLi Pharmaceutical Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Debt vs. Equity Structure

• Debt-to-asset ratio: projected decline from 41.5% (2023) to 27.1% (2026), reflecting deleveraging and/or faster asset growth relative to liabilities.
• Share repurchase program (as of 2025-07-31): 7,869,300 shares repurchased, representing 1.92% of issued shares, at a total cost of ¥99,954,426.00.
• Market capitalization (2025-10-09): ¥5.08 billion - a 4.20% increase year-over-year.
• Enterprise value: ¥5.62 billion, signaling modest net-debt-adjusted valuation above market cap.
• Valuation and risk metrics: P/E = 21.64; Beta = 0.82 (lower volatility vs. market).

• Implications for investors:
  • Lower debt-to-asset ratio reduces financial distress risk and increases capacity for capital allocation to capex, M&A, or R&D.
  • Share buybacks (1.92% of shares) signal use of free cash flow to support EPS and return capital.
  • Enterprise value modestly above market cap suggests net debt is present but not excessive; monitor cash vs. debt trends.
  • P/E of 21.64 implies moderate earnings-based valuation - pair with growth outlook and margin stability when assessing price fairness.
  • Beta of 0.82 indicates relative defensive characteristics vs. broader market swings.

GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Liquidity and Solvency

GuiZhou SanLi Pharmaceutical reported operating cash flow of 107 million yuan in 2024, indicating solid cash generation from core operations. Capital expenditures totaled 45 million yuan in 2024, reflecting continued investment in production capacity and R&D.

• Operating cash flow (2024): 107 million yuan
• Capital expenditures (2024): 45 million yuan
• Short-term liquidity metrics (current ratio, quick ratio): not specified in available data
• Interest coverage ratio: not specified in available data
• Cash conversion cycle: not specified in available data
• Solvency ratio / long-term solvency metrics: not specified in available data

For broader context on the company's background and strategy, see: GuiZhou SanLi Pharmaceutical Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Valuation Analysis

Key market and valuation metrics for GuiZhou SanLi Pharmaceutical indicate a moderate market valuation with a shareholder yield component via dividends. Below are the principal figures investors should note as of October 9, 2025.

• Market capitalization: 5.08 billion yuan (up 4.20% over the past year)
• Price-to-Earnings (P/E): 21.64 - suggests moderate valuation relative to reported earnings
• Price-to-Sales (P/S): 2.87 - indicates a middle-range valuation relative to revenue
• Dividend per share: 0.34 yuan; Dividend yield: 2.82% - provides a modest cash return to shareholders
• Price-to-Book (P/B): not specified in available data
• EV/EBITDA: not specified in available data

• Missing P/B and EV/EBITDA metrics limit complete valuation cross-checks (book-value and cash-profitability lenses).
• Given the P/E of 21.64 and P/S of 2.87, relative valuation should be checked against peers and sector medians to determine whether the stock is fairly priced, expensive, or discount-priced.
• Dividend yield of 2.82% may be attractive to income-oriented investors but should be assessed alongside payout sustainability and earnings stability.

For context on corporate direction and long-term goals that can affect valuation drivers, see: Mission Statement, Vision, & Core Values (2026) of GuiZhou SanLi Pharmaceutical Co.,Ltd.

GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) - Risk Factors

Key financial metrics and projections highlight both growth potential and salient risks investors should monitor closely.

• Profitability pressure: net profit margin for the first three quarters of 2024 was 13.74%, down 2.50 percentage points year-on-year, signaling compression in margins and/or higher costs.
• Near-term earnings softness: EPS for Q1 2025 was 0.10 yuan versus 0.14 yuan in Q1 2024, reflecting lower quarterly profitability and potential volatility in operating results.
• Projected net profit trajectory: management/analyst projections show net profit of 354 million yuan (2024), 458 million yuan (2025), and 583 million yuan (2026), with year-on-year growth of 20.9%, 29.4%, and 27.2% respectively - indicating expected recovery but also reliance on execution.
• Leverage dynamics: reported debt-to-asset ratio is expected to decline from 41.5% (2023) to 27.1% by 2026, improving balance-sheet stability but reflecting historically higher leverage that could have constrained flexibility.
• Investment-related drag: capital expenditures in 2024 totaled 45 million yuan, pointing to ongoing investment in production and R&D that may depress short-term margins while aiming to support medium-term growth.
• Interest coverage uncertainty: the available data does not specify an interest coverage ratio, making external assessment of the company's ability to service interest-bearing debt incomplete and a material informational gap.

• Operational execution risk: achieving the projected net profit growth rates (20.9%-29.4% annually) requires sustained sales growth, margin recovery, and successful ROI on the 45 million yuan capex; shortfalls would materially affect guidance.
• Margin sensitivity: a 2.5 percentage-point drop in net margin year-on-year implies sensitivity to raw material, manufacturing, or SG&A cost swings-adverse input-price or pricing pressures could further compress returns.
• Leverage tail risk: while debt-to-asset is forecast to improve to 27.1% by 2026, prior higher leverage (41.5% in 2023) combined with opaque interest-coverage data increases refinancing and solvency risk under stress scenarios.
• Liquidity and disclosure gaps: absence of a disclosed interest coverage ratio and limited detail on cashflow generation trends reduce visibility into the firm's ability to service debt and fund capex without equity or new borrowings.
• Earnings volatility: quarterly EPS decline (Q1 2025 vs Q1 2024) suggests earnings volatility that could amplify stock price swings and investor risk, especially if growth depends on one-off product launches or market timing.
• Execution concentration: reliance on successful roll-out of capacity/R&D funded by current capex implies execution risk-delays or lower-than-expected commercial uptake would impact projected margins and net profit.

For broader context on the company's stated direction and values that may affect strategic decisions, see: Mission Statement, Vision, & Core Values (2026) of GuiZhou SanLi Pharmaceutical Co.,Ltd.

GuiZhou SanLi Pharmaceutical Co.,Ltd (603439.SS) Growth Opportunities

• Hanfang integration: +46% revenue contribution (post-integration impact on consolidated sales).
• 'Kaitoujian' spray: >20% revenue growth contribution in Q2 2024 driven by volume and channel gains.
• Market sentiment: market capitalization of ¥5.08 billion as of 2025-10-09, a 4.20% increase over the prior 12 months.
• Risk profile: beta = 0.82, indicating lower volatility vs. broader market - attractive for risk-averse investors.

• Revenue trajectory: modeled compound growth from ¥2.333B (2024) to ¥3.667B (2026) implies strong mid-term expansion driven by product strength and M&A synergies.
• Profitability: net profit rising from ¥354M (2024) to ¥583M (2026) with double-digit YoY increases reflects operating leverage and improved margin capture.
• Valuation context: ¥5.08B market cap (2025-10-09) with modest 12-month appreciation (4.20%) - suggests room for re-rating if growth execution continues.
• Volatility and suitability: beta 0.82 supports positioning for investors seeking lower-beta exposure in the healthcare/pharmaceutical segment.